管理儿科心力衰竭的挑战,特别是在资源有限的环境中
Lamk Kadiyani1, Sivasubramanian Ramakrishnan1
1Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
Annals of pediatric cardiology
|February 23, 2026
概括
由于独特的病理生理学和有限的儿科数据,儿童心力衰竭 (HF) 管理需要量身定制的方法. 更多的大规模试验对于优化全球儿童治疗策略至关重要.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心血管研究研究心血管研究
- 翻译医学是一种翻译医学.
背景情况:
- 儿童心力衰竭 (HF) 呈现出明显的全球流行病学特征,与成人HF不同.
- 先天性心脏病和心肌病在发达国家普遍存在,而风湿性心脏病在低收入和中等收入国家占主导地位.
- 儿科HF病理生理学,包括心脏生理学,分子信号和心室重塑,与成人相比是独一无二的.
研究的目的:
- 审查儿童心力衰竭的独特病理生理学,诊断挑战和不断发展的管理策略.
- 突出儿童HF护理中成人数据和分类系统的局限性.
- 强调需要进行儿科专用临床试验,以改善全球结果.
主要方法:
- 关于儿科心力衰竭的综合文献综述.
- 对流行病学数据和儿科和成人高血压之间的病理生理学差异的分析.
- 评估当前和新兴的治疗策略,包括"四大支柱"疗法和手术干预.
主要成果:
- 儿科HF诊断因非特异性症状和不充分的成人衍生工具而复杂化.
- 新兴疗法,如 ангиотензин受体-内普利素抑制剂显示出有前途,但需要儿科验证.
- PANORAMA-HF试验表明,萨库比特里尔/瓦尔萨坦在儿童中的疗效与埃纳拉普利尔相当,但没有统计学上优异的结果.
- 心室辅助器件和心脏移植仍然对末期儿科HF至关重要,面临着供体限制.
结论:
- 儿科HF需要特殊的方法,与成人护理不同.
- 目前的管理很大程度上依赖于推断成人的数据,这突显了关键的证据缺口.
- 紧急实施大规模的儿科专用临床试验对于优化儿童全球HF管理至关重要.
相关概念视频
01:30Heart Failure V: Medical Management
399
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
399
01:30Heart Failure VII: Nursing Interventions
576
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
576
01:22Heart Failure VI: Adjunct Therapies
438
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
438
01:29Cardiomyopathy VI: Nursing Management
382
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
382
01:17Pathophysiology of Heart Failure
4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
648
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
648